Jade Biosciences, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Jade Biosciences, Inc. (JBIO) reported Net Income (Loss) Available to Common Stockholders, Basic of -$100.14 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-05-07
- Jade Biosciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$26.74M.
- Jade Biosciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$19.09M.
- Jade Biosciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$38.17M.
- Jade Biosciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-12-31 was -$30.11M.
- Jade Biosciences, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$100.14M.
- Jade Biosciences, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$69.63M.
- Jade Biosciences, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$75.52M.
- Jade Biosciences, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$51.51M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | -$26.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$45.83M derived: sum of 2 quarters · filed 2026-03-06 | -$100.14M 10-K · filed 2026-03-06 | ||
| 2025-09-30 | -$19.09M 10-Q · filed 2025-11-14 | -$73.39M 10-Q · filed 2025-11-14 | |||
| 2025-03-31 | -$38.17M 10-Q · filed 2026-05-07 | -$2.52M 10-Q · filed 2025-04-25 | -$68.28M derived: sum of 2 quarters · filed 2026-05-07 | -$85.15M derived: sum of 3 quarters · filed 2026-05-07 | -$109.92M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$30.11M derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-06 | -$46.98M 10-K · filed 2026-03-06 | -$71.75M derived: sum of 3 quarters · filed 2026-03-06 | -$69.63M 10-K · filed 2025-03-27 | |
| 2024-09-30 | -$16.28M 10-Q · filed 2025-11-14 | -$16.24M 10-Q · filed 2024-11-12 | -$41.64M derived: sum of 2 quarters · filed 2025-11-14 | -$64.20M 10-Q · filed 2024-11-12 | -$85.24M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$24.77M 10-Q · filed 2024-08-12 | -$47.96M 10-Q · filed 2024-08-12 | -$68.37M derived: sum of 3 quarters · filed 2025-04-25 | -$87.94M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-03-31 | -$23.19M 10-Q · filed 2025-04-25 | -$43.60M derived: sum of 2 quarters · filed 2025-04-25 | -$63.16M derived: sum of 3 quarters · filed 2025-04-25 | -$82.19M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2023-12-31 | -$20.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$39.98M derived: sum of 2 quarters · filed 2025-03-27 | -$59.00M derived: sum of 3 quarters · filed 2025-03-27 | -$75.52M 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$19.56M 10-Q · filed 2024-11-12 | -$38.59M derived: sum of 2 quarters · filed 2024-11-12 | -$55.11M 10-Q · filed 2024-11-12 | -$70.13M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$19.02M 10-Q · filed 2024-08-12 | -$35.55M 10-Q · filed 2024-08-12 | -$50.57M derived: sum of 3 quarters · filed 2024-08-12 | -$64.16M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$16.52M 10-Q · filed 2024-05-13 | -$31.54M derived: sum of 2 quarters · filed 2024-05-13 | -$45.13M derived: sum of 3 quarters · filed 2024-05-13 | -$57.12M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | -$15.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$28.61M derived: sum of 2 quarters · filed 2024-03-25 | -$40.60M derived: sum of 3 quarters · filed 2024-03-25 | -$51.51M 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$13.59M 10-Q · filed 2023-11-13 | -$25.58M derived: sum of 2 quarters · filed 2023-11-13 | -$36.49M 10-Q · filed 2023-11-13 | -$44.71M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$11.99M 10-Q · filed 2023-08-14 | -$22.90M 10-Q · filed 2023-08-14 | -$31.12M derived: sum of 3 quarters · filed 2023-08-14 | -$37.31M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$10.91M 10-Q · filed 2023-05-15 | -$19.13M derived: sum of 2 quarters · filed 2023-05-15 | -$25.32M derived: sum of 3 quarters · filed 2023-05-15 | -$31.10M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$8.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$14.41M derived: sum of 2 quarters · filed 2023-03-29 | -$20.19M derived: sum of 3 quarters · filed 2023-03-29 | -$22.98M 10-K · filed 2023-03-29 | |
| 2021-09-30 | -$6.18M 10-Q · filed 2022-11-14 | -$11.97M derived: sum of 2 quarters · filed 2022-11-14 | -$14.76M 10-Q · filed 2022-11-14 | -$18.43M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$5.78M 10-Q · filed 2022-08-15 | -$8.58M 10-Q · filed 2022-08-15 | -$12.24M derived: sum of 3 quarters · filed 2022-08-15 | -$14.70M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | -$2.79M 10-Q · filed 2022-05-16 | -$6.46M derived: sum of 2 quarters · filed 2022-05-16 | -$8.92M derived: sum of 3 quarters · filed 2022-05-16 | -$11.12M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$3.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$6.13M derived: sum of 2 quarters · filed 2022-03-30 | -$8.33M derived: sum of 3 quarters · filed 2022-03-30 | -$9.76M 10-K · filed 2022-03-30 | |
| 2020-09-30 | -$2.46M 10-Q · filed 2021-11-15 | -$4.66M derived: sum of 2 quarters · filed 2021-11-15 | -$6.10M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$2.20M 10-Q · filed 2021-08-16 | -$3.64M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |